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Abstract
Objective: The use of haplotypes to impute the genotypes of unmeasured single nucleotide variants
continues to rise in popularity. Simulation results suggest that the use of the dosage as a onedimensional summary statistic of imputation posterior probabilities may be optimal both in terms of
statistical power and computational efficiency; however, little theoretical understanding is available to
explain and unify these simulation results. In our analysis, we provide a theoretical foundation for the use
of the dosage as a one-dimensional summary statistic of genotype posterior probabilities from any
technology. Methods: We analytically evaluate the dosage, mode and the more general set of all onedimensional summary statistics of two-dimensional (three posterior probabilities that must sum to 1)
genotype posterior probability vectors. Results: We prove that the dosage is an optimal one-dimensional
summary statistic under a typical linear disease model and is robust to violations of this model.
Simulation results confirm our theoretical findings. Conclusions: Our analysis provides a strong
theoretical basis for the use of the dosage as a one-dimensional summary statistic of genotype posterior
probability vectors in related tests of genetic association across a wide variety of genetic disease models.
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Abstract
Objective: The use of haplotypes to impute the genotypes of unmeasured single nucleotide
variants continues to rise in popularity. Simulation results suggest that the use of the dosage as a
one-dimensional summary statistic of imputation posterior probabilities may be optimal both in
terms of statistical power and computational efficiency, however little theoretical understanding
is available to explain and unify these simulation results. In our analysis, we provide a theoretical
foundation for the use of the dosage as a one-dimensional summary statistic of genotype
posterior probabilities from any technology.
Methods: We analytically evaluate the dosage, mode and the more general set of all onedimensional summary statistics of two-dimensional (three posterior probabilities that must sum
to 1) genotype posterior probability vectors.
Results: We prove that the dosage is an optimal one-dimensional summary statistic under a
typical linear disease model and is robust to violations of this model. Simulation results confirm
our theoretical findings.
Conclusions: Our analysis provides a strong theoretical basis for the use of the dosage as a onedimensional summary statistic of genotype posterior probability vectors in related tests of genetic
association across a wide variety of genetic disease models.

Introduction
Access to high-throughput genotype data has facilitated the process of identifying the genetic
component of complex diseases through genome-wide association studies (GWAS). However,
directly measured genotype data often only covers a fraction of known single nucleotide
polymorphisms (SNPs). Increasingly, genetic analyses leverage linkage disequilibrium (LD) to
impute untyped SNPs. Analysis at untyped SNPs using LD information from reference panels,
such as The International HapMap Project (T. I. H. 3 Consortium, 2010) or the 1000 genomes
project (T. 1000 G. P. Consortium, 2010), has already yielded promising disease loci for major
depressive disorder (Sullivan, Patrick F, de Geuss, Eco JC, Willemsen & James, Michael R,
Smit, Jan H, Zandbelt, Tim, Arolt, Volker, Baune, 2009), Crohn's disease (Barrett et al., 2008),
and prostate cancer (Zabaleta et al., 2009) among others.
While many imputation algorithms exist (e.g., MaCH (Li, Yun, Willer, Cristen J, Ding,
Jun, Scheet, Paul, Abecasis, 2010), IMPUTE (Howie, Donnelly, & Marchini, 2009), among
others), most algorithms generate a set of three posterior probabilities for each individual at each
imputed SNP, representing the relative likelihood that the individual is actually each of the three
possible genotypes at the SNP locus. While some exceptions exist (e.g., Lin et al. 2008), Hu and
Lin (2010)), most researchers attempt to use a one-dimensional summary statistic of the twodimensional posterior probabilities vector (three posterior probabilities that must sum to 1) in
place of the (unknown) true genotype in downstream statistical analyses. Common choices for
the one-dimensional summary statistics are the mode and the weighted mean (dosage) of the
three posterior probabilities. While posterior probabilities are common for imputed genotypes
they also occur when using next-generation sequencing data and SNP microarray technology.

Recently, extensive simulations demonstrated that the dosage retained enough
information that, in most realistic settings, the use of computationally intensive mixture models
which account for the entire posterior probability vector improved power negligibly over a
simpler, faster analysis using the dosage (Zheng, Li, Abecasis, & Scheet, 2011). Furthermore, the
dosage consistently outperformed the mode.
Despite these simulation results, little theoretical work has been conducted to consider
whether the dosage will always perform optimally relative to the mode. Furthermore, while the
dosage is a reasonable choice of one-dimensional summary statistic, it is unknown if more
optimal summary statistics are available. In the following manuscript we provide analytic proof
that across a variety of disease models dosage will always outperform the mode. We then show
that the dosage is equivalent to the optimal one-dimensional summary statistic up to a
perturbance term which is essentially zero in all practical situations. We confirm our analytic
results using simulation.

Methods
The following subsections are organized as follows. First, we provide an overview of our
notation and the main genetic disease model under consideration. We then provide proof that the
score test using the dosage is equivalent to the score test using the entire vector of posterior
probabilities. We then show that the dosage outperforms the mode and is, in fact, the optimal
choice of one-dimensional summary statistic across linear genetic disease models, and is a robust
choice for non-linear models. We conclude the methods section by describing simulation
analyses used to confirm the analytic results.

Basic notation and disease model
Individual genotypes provided by imputation software, as well as some SNP microarray and
sequencing technology, are typically provided for each individual, , as a vector of three
posterior probabilities,
has

(

), where

minor alleles,

is the posterior probability that individual

at a SNP of interest. The vector of posterior probabilities,

be interpreted as suggesting that the true minor allele count for individual , denoted

, can

, can be

modeled as being a single random draw from a multinomial distribution with probabilities
indicated by

. We assume that

is known for each individual. Let

be an indicator for

disease status and let the probability of disease for individual be given as

( ( )) where

formulation for the disease-genotype relationship is
We assume that
of

is a smooth function and

( ) A general
(

)

is a parameter vector constrained so that the range

is some subset of the unit interval. We will use the term additive model, to mean that the

function

depends on

and

only through a term of the form

explore two types of additive models (1) A linear additive model:
(nonlinear) logistic additive model,

. When

(2) and a

is unobserved, it is common to

naively plug in a one-dimensional summary statistic such as the mode,
the dosage,

. In this manuscript we

, or

, for the genotype in the disease model.

Score Test Using the Posterior Probability Vector
Intuitively, we anticipate a loss of information when summarizing the entire posterior probability
vector with a one-dimensional summary statistic. However, we will now show for the commonly
used logistic model that a score test using the dosage is equivalent to a score test from a model
that incorporates the entire posterior probability vector.

The observed data likelihood of ̃ for a random sample of n individuals is given by
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We note that a score test is the score component, , divided by the negative derivative of
the score component, , which is known as the observed information. Thus, because

is

equivalent and the null models under either formulation admit the same distribution for , it

follows that the score tests for association are equivalent. When covariates are present,

and

depend on . The score statistic is computed by substituting ̂ , the MLE estimated under the
null model, in place of .

Optimal choice of a one dimensional summary statistic
While we have demonstrated that the score test using the dosage is equivalent to a score test
using the entire vector of posterior probabilities, we have not considered the power of such an
approach. The score test is known to perform well asymptotically, but we have no reason to
assume that the dosage will perform well in finite samples. In the following sections we explore
intuitive choices for , a general one-dimensional summary of the posterior probabilities, and
then derive its optimal value.

Explicit expression for the non-centrality parameter
In Appendix A, we assume a logistic model and provide the score statistic for any onedimensional summary, , of , the true genotype. We derive the statistic under the logistic model
because this is the most popular model choice in applied work. All subsequent power
calculations are performed with respect to this class of test statistics. Our goal is to evaluate the
power across a range of true models, which may or may not be logistic, seeing how the optimal
summary depends on various assumptions about the true model. An expression is given for the
noncentrality parameter when the true model has a general form,

(

), and an

analytically useful version results when we assume the true model is linear. Since a larger
noncentrality parameter is a necessary and sufficient condition for a more powerful test, in the

proceeding sections, we will use the noncentrality parameter to compare the efficiency of various
one-dimensional summaries, .

Dosage Beats Mode
In Appendix B, we prove that the dosage is more highly correlated with the true genotype than
the mode. This result makes no assumptions about the form of the true disease model (e.g., linear
or logistic) and holds for all finite sample sizes. We note, however, that a higher correlation
between the imputed genotype and the true genotype does not automatically imply a more
powerful test. To draw conclusions about higher power from higher correlation alone, one must
also assume that the true disease model is linear:

. We consider non-linear

models more explicitly later (Nonlinear Disease Models).

Optimal Summary of Posterior Distribution
Although the superiority of the dosage to the mode is an important result, we have not yet
demonstrated that the dosage is an optimal one-dimensional summary statistic. In Appendix C,
we show that the score test which results from using the dosage is essentially identical to a score
test using the optimal one-dimensional statistic. In Appendix C, we start by noting that the
optimal one-dimensional statistic yields the test with the largest noncentrality parameter. Finding
the optimal statistic is therefore equivalent to finding the statistic which maximizes the
noncentrality parameter defined in Appendix A. Results from perturbation theory show that the
dosage is nearly identical to the optimal statistic in all realistic situations. When the true disease
model is linear, it follows that the score test using the dosage is essentially optimal.

Taylor series expansions show that an additive logistic disease model is well
approximated by a linear model when disease prevalence is low for all genotype groups or the
SNP effect size is small. Additionally, we expect the projection of the additive logistic model
onto the space of all linear models to result in a model respecting the range of
subset of the unit interval, since

, namely some

is bounded and only takes three values. For cases in which

this linear approximation is inadequate, our results in the section Score Test Using the Posterior
Probability Vector still apply. These results serve as insurance that the dosage will perform
strongly in the case of an additive logistic model, that it will be asymptotically optimal since the
score test is asymptotically most powerful. However, there is no longer any claim on optimality
in finite samples when the additive logistic model is not well approximated by a linear model.

Nonlinear Disease Models and Covariates
The previous sections assumed either a linear or approximately linear disease model. While the
assumption of approximate linearity is common in practice with the use of a logistic model, we
now consider non-linear modes of inheritance. We first analyze the situation without covariates.
In Appendix D we derive the optimal score test for this case. As in the case of a linear model, the
optimal statistic for a nonlinear model is well approximated by a simple one-dimensional
statistic. Specifically, an approximation of the optimal statistic is given by a linear combination
of the dosage and a generalization of the dosage which we call the second-order dosage. This
linear combination is given by
dosage (which governs the

( )

( )

, where

order effect) for

first order effects, a measure of non-linearity.

( )

represents the
and

order

represents the ratio of the second to

To build some intuition about , let us examine two common non-linear models. For a dominant
disease model use

instead of the dosage, and for a recessive disease model use

instead of the usual dosage. For more complex models, we can formulate the intuition behind
as follows. The posterior distribution of the genotype can be indexed by two parameters: the
mean and the variance. For linear and approximately linear models, one can simply pretend that
with little cost. For nonlinear models, the cost is non-trivial. The variance in the
posterior distribution should then inform us on an individual basis of the cost of the assumption
, and allow us to adjust the weight of evidence accordingly.
Appendix D shows that the only change to our analysis through the inclusion of
covariates is to allow the nonlinearity of the SNP effect to depend on the values of the covariates.
Implementation wise, the optimal linear combination is now
of effect nonlinearity,

depends on

( )

( )

( )

where the measure

. Such complications can be avoided if the SNP and

covariate effects are additively separable,

( )

( ), in which case a common

suffices to summarize nonlinearity of the SNP effect.

Continuous Traits
In Appendix E, we derive the optimal score test for normally distributed continuous traits which
are linear functions of the genotype and a set of covariates. Thus we have analytically shown that
the dosage is the optimal statistic for the additive continuous traits model considered in Zheng et
al. (2011).

Simulation

To verify the theoretical results empirically, we calculated power using simulated data. We
considered three different characteristics of SNPs: (1) the
the genotype (Note: this

coefficient between the dosages and

coefficient is the value that MACH approximates with its

imputation quality measure (Li, Yun, Willer, Cristen J, Ding, Jun, Scheet, Paul, Abecasis, 2010))
(2) the minor allele frequency, which unless otherwise stated was set at 0.1 and (3) the odds ratio
under an additive disease model. We consider values of

ranging from 0.1 to 1, MAF ranging

from 0.05 to 0.5 and odds ratios ranging from 1.0 to 2.0. For each simulation setting 10,000
SNPs were simulated with 1000 cases and 1000 controls. Disease prevalence was fixed at 50%
among individuals with no risk alleles. Unless otherwise stated, power was calculated at the 5%
significance level using the asymptotic distributions of the score tests.

For each SNP and each individual we compute posterior probabilities
Dirichlet distribution, where

(

)

indicate the minor allele frequency of the SNP and
the desired

(

(

)

by sampling from a
(

)

). We let

be a nonnegative constant chosen to obtain

. Varying does not appear to greatly modify the standard deviation of the

coefficient, which ranges between 0.02 and 0.03 across all simulations. An individual’s genotype
was determined by sampling from a multinomial distribution with probabilities indicated by
the vector of posterior probabilities

.

Results
We conducted simulation analyses to confirm the theoretical findings described earlier. In the
following sections we briefly describe the results of these simulation analyses. Figure 1
empirically demonstrates that the score test for the dosage is uniformly more powerful than the
test for mode. In this setting we note that the power for the true genotype test is much higher than

the power for both the dosage and mode score tests. However, this is not surprising given the
relatively low imputation quality (r2=0.6), used in this graph.
As expected, as imputation quality increases, power increases (Figure 2). Furthermore,
the power of the dosage and mode tests approaches the power of the linear trend test using the
true genotype as r2 increases. We note that, for

, all three tests are identical and thus

obtain the same power. On the other hand, for low

the dosage and mode contain little

information about the true genotype, and so low power is obtained. Nonetheless, it is interesting
to see that the dosage outperforms the mode even in this setting.
Figure 3 shows that the power of all methods increases as the log odds ratio increases.
When the odds ratio is 1 the power is equivalent to type I error rate. Importantly, all methods
control type I error with empirical type I error rates equal to the nominal rate of 0.05 (detailed
results not shown). For larger odds ratios we find the expected result that true genotypes are
more powerful than dosages, which are in turn more powerful than the mode. As odds ratios
grow sufficiently large all methods have power approaching 1, though the power rankings of the
three methods remains.
Lastly, Figure 4 shows that power decreases as minor allele frequency decreases. While
all tests of association are low powered at a minor allele frequency of 0.05, relative power
ordering still holds for the methods, with the true genotype yielding the highest power at 0.40,
the dosage yielding the second highest power at 0.26, and the mode yielding the lowest power at
0.22.
We also compared the dosage to the optimal summary statistic given as a dominant
eigenvector in Appendix C. Simulations showed that the power and type I error were virtually
identical using the two statistics (detailed results not shown).

Discussion
Previous work has shown that the computational overhead may not be worth the modest
power gain from using the entire vector of posterior probabilities instead of the weighted mean
posterior probability (dosage). In our analysis, we provided analytic proof that the dosage is
essentially equivalent to the optimal choice of a single summary statistic in all practical
situations across a range of genetic disease models, far exceeding the power obtained from using
the modal posterior probability. These results were confirmed via simulation.
There are a number of important implications of these conclusions. First, while
theoretical results and simulations considered the score test, due to the asymptotic equivalence,
the optimality of the dosage extends to the related likelihood ratio and Wald tests. Furthermore,
as considered in Appendix D, extensions to models including covariates show similar results,
unless the effects of covariates are very large.
Superficially, our results may seem to depend (i) on the assumption that the true model is
linear or approximately linear and (ii) on asymptotic approximations via Taylor expansions.
However, two facts show that our results should have broad applicability across a range of
models and for finite samples. First, the dosage is the one dimensional summary most highly
correlated with the true genotype. This holds for all sample sizes and regardless of the true
disease model. Second, naïvely assuming
model

∑

(

)
(

)

(

)
(

)

in place of the actual mixture

does not change the resulting score statistic. Since it is well

known that an additive logistic disease model is robust to misspecification (Friedlin B et al.,

2002), this suggests that the score statistic from the naïve model,
the score statistic from the true mixture model,

∑

( ), well approximates

( )

Additionally, as shown in Appendix D, in many realistic non-linear models, the dosage
remains a nearly optimal choice of one-dimensional statistic because the degree of nonlinearity is
negligible. Even when non-linearity of the SNP effect is appreciable, Appendix D shows that to
the extent that the non-linearity can be explicitly described, simple adjustments to the optimal
one-dimensional summary can be made to preserve efficiency. Trivially, for a dominant disease
model use

instead of the dosage, and for a recessive disease model use

instead of

the usual dosage. A method for choosing the optimal summary statistic for more complex models
can be found in Appendix D. In additional simulation analyses, not shown here, the dosage
showed robustness across a wide-variety of non-linear models, with robustness related to the
extent of non-linearity.
For continuous responses, Zheng et al. (2011) implemented a mixture model utilizing the
entire vector of posterior probabilities. In analyses not reported here, we did similarly with an EM algorithm and found that, like Zheng, dosage performed similarly with far less computational
expense. In Appendix E we outline the proof of optimality of the dosage under a normal linear
model for a quantitative response. While we did not provide simulations here, extensive
consideration of this model and deviations from it can be found in Zheng et al. (2011). These
extensive simulations also consider cases with sample sizes as low as 50 (Zheng et al.; Figure 3)
suggesting robustness to the asymptotic assumptions underlying portions of the results shown
here.
While we do not consider the new class of rare variant tests explicitly, our results may be
extendable to two classes of rare variant tests, with a word of caution. For rare variant tests

which collapse rare variants into a single “super variant”, the dosage is given by the probability
that any one of the included variant sites contains the rare variant, that is by

∏

, where

represents the posterior probability for person not having a rare variant at site . For rare
variant tests which regress the total number of rare variants present across a set of variant sites,
the modified dosage is given by ∑
the approximation ∑
additively, ∑
∑

∑
∑

. The former is really a special case of the latter based on
. Suppose that the variants enter into the disease model

. Then our results apply by thinking about the imputation of

which now depends not only on the posterior probabilities for each

nuisance parameters

but also on the

. How to effectively estimate the nuisance parameters remains an area of

active research. However, given the nuisance parameters, our results suggest that a near optimal
summary would be ∑

. In particular, one may justify use of ∑

by assuming

homogeneity of effects across variants. Caution needs to be taken for small sets of variant sets or
sample sizes, however, because in these cases the perturbation term by which the dosage differs
from the optimal summary may be nontrivial. Simulation studies and further analysis of these
rare variant strategies, along with consideration of the recently proposed class of variancecomponents tests, is needed.
Few assumptions are required on the posterior probabilities in order for the results
described here to be valid. In particular, posterior probabilities, while commonly obtained from
imputation, can also be obtained from both SNP microarray and next-generation sequencing
technologies. The analytic calculations shown here directly extend to these platforms. The main
necessary assumption about the posterior probabilities is that they are correctly calibrated—
namely, that the vector of posterior probabilities,

, can be interpreted as suggesting that the

true minor allele count for individual , denoted

, can be modeled as being a single random

draw from a multinomial distribution with probabilities indicated by

. While this interpretation

is almost uniformly made in practice, any systematic technological bias could impact this
interpretation, making the analytic conclusions provided above no longer hold.
The dosage is commonly used as a shortcut to use of a wide-class of statistical methods,
which assume knowledge of the true genotypes. We provide analytic justification of its use
across a wide variety of genetic models.

Acknowledgements
We acknowledge the work of Jennifer James and Nathaniel Bowerman in early phases of this
project. This work was funded by the National Human Genome Research Institute
(R15HG004543; R15HG006915). We acknowledge the use of the Hope College parallel
computing cluster for assistance in data simulation and analysis.

References
Barrett, J. C., Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et
al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for
Crohn’s disease. Nature genetics, 40(8), 955–62. doi:10.1038/ng.175
Consortium, T. 1000 G. P. (2010). A map of human genome variation from population-scale
sequencing. Nature, 467(7319), 1061–73. doi:10.1038/nature09534
Consortium, T. I. H. 3. (2010). Integrating common and rare genetic variation in diverse human
populations. Nature, 467(7311), 52–8. doi:10.1038/nature09298
Friedlin B., Zheng, G., Li, Z., & Gastwirth, J.L. (2002) Trend tests for case-control studies of
genetic markers: power, sample size and robustness. Human Heredity, 53, 146-52.
Howie, B. N., Donnelly, P., & Marchini, J. (2009). A flexible and accurate genotype imputation
method for the next generation of genome-wide association studies. PLoS genetics, 5(6),
e1000529. doi:10.1371/journal.pgen.1000529

Hu, Y. J., & Lin, D. Y. (2010). Analysis of untyped SNPs: maximum likelihood and imputation
methods. Genetic epidemiology, 34(8), 803–15. doi:10.1002/gepi.20527
Lang, B. (2000). Direct Solvers for Symmetric Eigenvalue Problems. In J. Grotendorst (Ed.),
Modern Methods and Algorithms of Quantum Chemistry (pp. 231–259). Julich: John von
Neumann Institute for Computing.
Li, Yun, Willer, Cristen J, Ding, Jun, Scheet, Paul, Abecasis, G. R. (2010). MaCH: Using
sequence and genotype data to esimate haplotypes and unobserved genotypes. Genetic
epidemiology, 34(8), 816–834. doi:10.1002/gepi.20533.MaCH
Lin, D. Y., Hu, Y., & Huang, B. E. (2008). Simple and Efficient Analysis of Disease Association
with Missing Genotype Data. American Journal of Human Genetics, 82(February), 444–
452. doi:10.1016/j.ajhg.2007.11.004.
Sullivan, Patrick F, de Geuss, Eco JC, Willemsen, G., & James, Michael R, Smit, Jan H,
Zandbelt, Tim, Arolt, Volker, Baune, B. T. (2009). Genomewide association for major
depressive disorder: A possible role for the presynaptic protein Piccolo. Molecular
Psychiatry, 14(4), 359–375. doi:10.1038/mp.2008.125.
Wu, M.C., Lee, S., Cai, T., Li, Y., Boehnke, M., and Lin, X. (2011). Rare-variant association
testing for sequence data with the sequence kernel association test. American Journal of
Human Genetics 89(July), 82-93. doi: 10.1016/j.ajhg.2011.05.029
Zabaleta, J., Su, L. J., Lin, H.-Y., Sierra, R. a, Hall, M. C., Sartor, a O., Clark, P. E., et al. (2009).
Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis,
30(8), 1358–62. doi:10.1093/carcin/bgp124
Zheng, J., Li, Y., Abecasis, G. R., & Scheet, P. (2011). A comparison of approaches to account
for uncertainty in analysis of imputed genotypes. Genetic epidemiology, 35(2), 102–10.
doi:10.1002/gepi.20552

Appendix A
Much of the derivation of the non-centrality parameter follows Wu et al. (2011). The logistic
model utilizing a general one-dimensional summary of the posterior genotype distribution,
( ( )) where

can be written as

( )

,

. Following arguments

made in the main text (Methods: Score Test Using the Posterior Probability Vector), we can
denote the squared score component as (
(

̂ )

(

̂ ) where

(

),

) and ̂ as the vector of disease probabilities estimated under the null hypothesis.

We note that when the SNP is typed,

and the above corresponds to the Armitage linear

trend test.
(

Define

) as the vector of differences between the true disease

probability and the null disease probability. Under
( (

, we have
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)). The squared score component can be rewritten as follows
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, only one of the eigenvalues is non-zero and we take this to be
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has mean
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where

is the noncentrality parameter, and

‖

‖‖ ̃ ‖

‖ ̃ ‖ since

̃

̃

(

⁄
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Thus the quantity which determines power is
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is the angle between

and ̃ , i.e. how well the summary of the posterior genotype distribution
ways in which the truth deviates from the null hypothesis, ̃

(

̃ )

⁄

is aligned with the

̂ .

Consider the special case of a disease model which is truly linear,
this model

̃

‖ ̃ ‖ is simply the length of

is orthonormal and

the projection of ̃ in the direction of

̃ ) . Note that

. Under

. The noncentrality parameter is
(
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(

well aligned our summary

‖ ‖‖ ‖) . Note that the key quantity is
is with the true genotype vector .

or how

Appendix B
We now consider the special cases of the score test from Appendix A where the one-dimensional
summary statistic

is equal to

correlation between

(dosage) or

(mode).

and the true genotype

is then the observed

and we show that the dosage is always more

highly correlated with the true genotype than is the mode. In this Appendix we assume that the
(

posterior probability vectors

) are drawn i.i.d from some arbitrary distribution

on the 2-simplex. We note that this implies
above when

and

are now both random variables whereas

was treated as fixed, the dosage and mode were also fixed. In other sections of

this paper we condition on

and thus we are able to treat them as constant.

Using the law of total covariance
(
Because given

,

)

(

(

))

( (

)

)

and

(

is a constant and thus

(

))

( )

(

). A second

application of the law of total covariance gives:
(
Let

)

(
(

represent

(

))

) and
(

)

( )
( )√

√

)

√

( )

(

( )
(

( )

(

√

( )

√

)

( )

√

(

)

(

)
(

)

(
(

)√
(

))

(

)

). Thus, by substitution, we have

( )
(

( )

(

(

represent

√

since

( (

)
( )

)
)

)

) by the Cauchy-Schwarz inequality.

So far, no asymptotic arguments have been used. Asymptotics come into play only in
linking

to

and

to

, where

counterparts of the sample quantities,

and

and

are the population

. The justification for using dosage

over mode in any particular sample depends on the inequality

rather than

the inequality

(Lang,

2000). Thus as

. As
,

,

and

almost surely. And so, based on the equation for

the noncentrality parameter shown in Appendix A, the test using the dosage has a larger
noncentrality parameter than the test using the mode, implying that the score test using the
dosage test has more power than the test using the mode.

Appendix C
For the set of linear trend tests using the statistic (
, where we define optimal to be the
Thus, to find the optimal

where

(

̂ ), we derive the optimal

which yields the most powerful score test.

we wish to maximize the noncentrality parameter

(see Appendix A) subject to the constraint that ‖
̃

̂ )

‖

̃ ̃

. Under the linear disease model,

is a multiplicative constant that is irrelevant to the optimization

problem. Thus we wish to solve the optimization problem given as follows:
( (
Because

)(

and the optimal

) ) subject to

is unique only up to scaling (significance of the test does

not depend on how we scale ), we can reformulate the problem as:
(

)

The first-order conditions are

( ( ) ( )
Thus

( )

)

is dominant eigenvector of
( ) ( )

( )

( )
( )

where
Let

*

(

).

be the dominant eigenvector of

, which ignores the covariance term. Below,

we justify why ignoring the covariance term has negligible effect in most situations. Note that
‖ ‖

and since the scaling on

does not matter for testing purposes, this suggests we take

if the covariance term can be ignored.

To justify approximating

with

*

, in essence why it is acceptable to ignore the
[

covariance term, we can assume without loss of generality that

]

( ). Applying a result from perturbation theory, see Equation 6 in [11], yields :

∑

( )

( )
∑
( )

(

( )

∑

where CV is the coefficient of variation where

We can interpret

( )

( )
( )

( )

)

(∑

( )

)

.

as a measure of of the signal to noise ratio (of the imputation

process) for individual i. Thus, ∑

( )

is a weighted sum that measures the overall

precision of the imputation process, where the weights,

( )
(

, serve as a standardization factor.

)

As n goes to infinity, the weighted sum of the precisions goes to infinity as well, i.e. there is an
accumulation of genotype information across individuals so that the angle between

and

goes to 0. Finally, we combine the bound with the following approximation for small angles,
to conclude that g* and g are essentially identical.

Finally, we note that, since the

’s are observed, one can always calculate

each study to find an upper bound on how much

and

for

are expected to differ. However, we

note that in our analyses, details not shown, for practical sample sizes,
close.

( )

and

will be very

Appendix D
We now consider more general disease models and study how a nonlinear effect of genotype
count on disease risk impacts the efficacy of one-dimensional summaries of the posterior
probability vector. Let
(

)

(

be the genotype of individual and

) and

model suggests that

( )

(

be a vector of covariates. Let

). Note that the inclusion of covariates in the

may vary between individuals, unlike in previous appendices. Because

has only three states, any

is sufficiently described by a quadratic fit through the three points,

and so without loss of generality we assume
(

)

is quadratic. Then:

( )

(

)

(

There are two assumptions we can make to simplify the analysis: (i)
(

)

) for all

( (

)

( ) is free of

(

values and (ii) that interactions between

)
is sufficiently linear in
and

are negligible

). A special form of (ii) occurs when we assume that the SNP and
( )

covariate effects are additively separable:

( ) and the

( ). Then

problem reduces to the case without covariates. If we make both assumptions (i) and (ii), then the
intuitions derived in Appendices B and C for a disease model where risk is linear in genotype
count are expected to hold. The logistic model belongs to this class, thus explaining why dosage
performs so well in this important case. To see this in the simple case of no covariates, let
( ) and Taylor expand this expression about the dosage
( )
One can show that

( )

(

( )(

)

)(

)

( )(

:

)

. A linear approximation to the

logistic model results if we can justify ignoring the second order term. The upper bound already
gives us some grounds for doing so. In addition,

( ) is near zero and thus negligible if

(low prevalence in a prospective cohort study), if

(approximately equal number of cases

and control in a case-control study), or if the SNP effect is small.
We now move towards an analysis applicable towards a general disease model by first
relaxing the assumption (ii), i.e., the effect of
̃

( (

where

. Then

)). The optimization problem for the non-centrality

(

parameter becomes

does not depend on the value of

)

. If

is far from being

proportional to the identity matrix, then this implies that the amount of “signal” we can expect
from different individuals is different on average. Thus the scheme which treats all individuals
equally is suboptimal.
We now relax assumption (i), linearity of the SNP effect. To optimize the noncentrality
(

parameter on average, we solve we solve
Recalling that

) subject to

represents the vector of differences between the true disease probability and

the null disease probability, it follows that from the Taylor series expansion that the
is given by (

)

( (

)

(

solution is the dominant eigenvector of

)
[ (

). Following the results of Appendix C, the
) (

)

(

Using the same arguments from perturbation theory, (
dimensional summary. Here, (
(

)

( )

, where

( )

(

)
( )

)

)

note that in most realistic situations (
the dosage vector, (

( (

(

)]

.

) is an essentially optimal one
)

)

(

gives what we call the
) (

vector

)

( )

order dosage. We

) will be large enough that the angle between

), and the optimal summary

will be essentially .

( )

Note that

is denoted d in the rest of this paper. The relative importance of the first-

order versus the second-order dosage in our optimal summary is determined by the relative
magnitudes of

(

) and

(

). If the effect on risk of the second allele differs

significantly from that of the first, i.e.

(

) is large in magnitude, then the first-order dosage

is an insufficient summary.
This is result is intuitive. The extent to which we need information beyond the dosage
depends on the extent to which the disease model is non-linear. Note that

(

) and

(

)

are not known, so implementing the optimal one-dimensional summary is infeasible for highly
nonlinear risk models unless one is willing to make an educated guess about the relative degree
of the second order effect. For example, if we believe that the second-order effect is some
fraction
would be

(

of the first-order effect,
( )

( )

)

(

) for all

, then an optimal summary

( ) may depend on the covariate value for each

. Otherwise

individual and the optimal summary for each individual would weight the first and second order
dosages differently,

( )

( )

freedom lost by trying to estimate
a better summary of

.

( )

. Note that in most cases

is unknown and the degree of

may more than outweigh any efficiency gain from obtaining

Appendix E
Suppose now that

vector of covariates for individual of length
where
(

(

is a quantitative trait. Let

). Further let

(

), where

is a constant length

is

)

(

and

column vector and

. The F-statistic testing

(
(

is a column

. Assume the normal linear model given by:

(

Where

) , where each

)
)

)

is

(

)

. The noncentrality parameter of the statistic is

an increasing function of:
(
is unknown. Suppose we replace

)

[

]
with ̂ ). The non-centrality

with ̂ (accordingly
[̂

parameter for the F-statistic from using ̂ is

]

. To maximize power, we again

maximize this noncentrality parameter. That is, we seek to solve the following optimization
problem:
̂

[

[

[̂

]

]

]

̂

[

[

̂]

]

The first-order condition can be given as (in the expectation below, note that ̂ is fixed since it
only depends on the covariates and hyperparameters governing the distribution of )
[

(

̂) ]

[

(

̂) ]

This says that if ̂ is optimal, then the column space of ̂ and
optimal solution is ̂

(

̂) [ ]
must contain [ ]. Thus one

[ ], the dosage. This solution may not be unique just as the basis

vectors of a vector space are not unique.

Figure 1 ROC Curve evaluating asymptotic significance of different approaches to summarizing
posterior probability vectors

Caption: The asymptotic power of the dosage approach dominates the power of the test when
using the mode, for all type I error rates. The figure illustrates the power of a test of case-control
association for a SNP with MAF=0.10, odds ratio =1.28, and 1000 cases and 1000 controls. In
this case the imputation r2 was 0.60. The relatively low imputation r2 explains why the dosage
and mode are not performing better relative to the power of the test when using the true
genotype.

Figure 2 Evaluating the power of the dosage and mode across different levels of imputation
accuracy

Caption: Regardless of imputation accuracy, the dosage provides a more powerful choice of
summary statistic than the mode. As expected, power increases as imputation accuracy increases.
The figure illustrates the power of a test of case-control association for a SNP with MAF=0.10,
odds-ratio=1.28, and 1000 cases and 1000 controls.

Figure 3 Evaluating the power of the dosage and mode across different values of the odds ratio

Caption For both small and large odds ratios, the dosage provided a more powerful alternative
than the mode. The figure illustrates the power of a test of case-control association for a SNP
with MAF=0.10, imputation r2=0.6, and 1000 cases and 1000 controls.

Figure 4 Evaluating the power of the dosage and mode across different minor allele frequencies

Caption Across all minor allele frequencies, the dosage provided a more powerful alternative
than the mode. The figure illustrates the power of a test of case-control association for a SNP
with odds ratio of 1.25, imputation r2=0.6, and 1000 cases and 1000 controls.

